Restriction of Human Cytomegalovirus Infection by Galectin-9.
Adult
Antiviral Agents
/ metabolism
Case-Control Studies
Cells, Cultured
Cytomegalovirus
/ pathogenicity
Cytomegalovirus Infections
/ metabolism
Fibroblasts
/ cytology
Galectins
/ metabolism
Hematopoietic Stem Cell Transplantation
Humans
Prospective Studies
Transplant Recipients
Virus Activation
Virus Internalization
Virus Replication
cytomegalovirus
human herpesviruses
virus-host interactions
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
received:
03
10
2018
accepted:
31
10
2018
pubmed:
30
11
2018
medline:
9
11
2019
entrez:
30
11
2018
Statut:
epublish
Résumé
Human cytomegalovirus (HCMV) is a ubiquitous human herpesvirus. While HCMV infection is generally asymptomatic in the immunocompetent, it can have devastating consequences in those with compromised or underdeveloped immune systems, including transplant recipients and neonates. Galectins are a widely expressed protein family that have been demonstrated to modulate both antiviral immunity and regulate direct host-virus interactions. The potential for galectins to directly modulate HCMV infection has not previously been studied, and our results reveal that galectin-9 (Gal-9) can potently inhibit HCMV infection. Gal-9-mediated inhibition of HCMV was dependent upon its carbohydrate recognition domains and thus dependent on glycan interactions. Temperature shift studies revealed that Gal-9 specific inhibition was mediated primarily at the level of virus-cell fusion and not binding. Additionally, we found that during reactivation of HCMV in hematopoietic stem cell transplant (HSCT) patients soluble Gal-9 is upregulated. This study provides the first evidence for Gal-9 functioning as a potent antiviral defense effector molecule against HCMV infection and identifies it as a potential clinical candidate to restrict HCMV infections.
Identifiants
pubmed: 30487283
pii: JVI.01746-18
doi: 10.1128/JVI.01746-18
pmc: PMC6340044
pii:
doi:
Substances chimiques
Antiviral Agents
0
Galectins
0
LGALS9 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2019 American Society for Microbiology.
Références
Drug Resist Updat. 2002 Apr;5(2):88-114
pubmed: 12135584
PLoS Pathog. 2015 Jul 06;11(7):e1004999
pubmed: 26147640
J Immunol. 2011 Dec 1;187(11):5745-55
pubmed: 22021615
J Immunol. 2005 Apr 1;174(7):4120-6
pubmed: 15778371
Antiviral Res. 2010 Mar;85(3):532-40
pubmed: 20083141
Hepatology. 2012 Oct;56(4):1342-51
pubmed: 22505239
J Virol. 2012 Sep;86(18):9854-65
pubmed: 22761372
J Virol. 2016 Oct 14;90(21):9766-9781
pubmed: 27558416
J Leukoc Biol. 2002 Sep;72(3):486-91
pubmed: 12223516
Blood. 2007 Aug 15;110(4):1326-9
pubmed: 17438085
Blood. 2003 Apr 1;101(7):2686-92
pubmed: 12411292
PLoS Pathog. 2010 Jul 15;6(7):e1000993
pubmed: 20657665
Blood. 2011 Apr 21;117(16):4315-22
pubmed: 21300977
J Leukoc Biol. 2016 Mar;99(3):495-503
pubmed: 26475932
J Immunol. 2017 Oct 15;199(8):2721-2728
pubmed: 28877989
J Virol. 2011 Nov;85(22):11742-51
pubmed: 21880749
Nat Cell Biol. 2013 Sep;15(9):1019-27
pubmed: 23999615
Future Microbiol. 2010 Jun;5(6):883-900
pubmed: 20521934
Nat Rev Immunol. 2009 May;9(5):338-52
pubmed: 19365409
J Virol. 2017 Jun 9;91(13):
pubmed: 28381568
J Virol. 2006 Jan;80(2):710-22
pubmed: 16378974
J Virol. 2013 Sep;87(17):9680-90
pubmed: 23804643
Retrovirology. 2013 Jul 18;10:74
pubmed: 23866914
Biochemistry (Mosc). 2011 Aug;76(8):958-67
pubmed: 22022970
Immunobiology. 2012 Jun;217(6):657-66
pubmed: 22204815
Curr Opin Virol. 2017 Jun;24:97-104
pubmed: 28538165
J Virol. 2011 May;85(10):5150-8
pubmed: 21367908
PLoS Pathog. 2017 Apr 12;13(4):e1006273
pubmed: 28403220
J Virol. 2004 Feb;78(3):1289-300
pubmed: 14722284
J Virol. 2012 Oct;86(19):10606-20
pubmed: 22811539
Retrovirology. 2008 Nov 25;5:105
pubmed: 19032754
Virology. 2013 Jan 20;435(2):239-49
pubmed: 23089254
PLoS One. 2010 Mar 04;5(3):e9504
pubmed: 20209097
PLoS One. 2014 Nov 13;9(11):e112474
pubmed: 25392933
Scand J Immunol. 2007 Aug-Sep;66(2-3):143-58
pubmed: 17635792
J Immunol. 2005 Jul 1;175(1):413-20
pubmed: 15972675
Med Res Rev. 2013 Jun;33 Suppl 1:E102-26
pubmed: 21793015
PLoS Biol. 2017 Dec 18;15(12):e2004086
pubmed: 29253856
J Clin Virol. 2009 Dec;46 Suppl 4:S6-10
pubmed: 19800841
Blood. 2012 May 3;119(18):4192-204
pubmed: 22438246
Int J Mol Sci. 2017 Jan 01;18(1):
pubmed: 28045432
Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10650-5
pubmed: 21670307
Virology. 1993 Nov;197(1):143-58
pubmed: 7692667
Tohoku J Exp Med. 2014;232(4):263-7
pubmed: 24695077
J Virol. 2008 Dec;82(23):11837-50
pubmed: 18815310
J Biol Chem. 2006 Feb 3;281(5):2661-7
pubmed: 16275647
Glycobiology. 2009 Jan;19(1):2-15
pubmed: 18815291
Rev Med Virol. 2010 Jul;20(4):202-13
pubmed: 20564615
Int J Immunopathol Pharmacol. 2005 Oct-Dec;18(4):615-23
pubmed: 16388708
J Virol. 2010 Mar;84(5):2585-96
pubmed: 20032184
Nat Immunol. 2005 Dec;6(12):1245-52
pubmed: 16286920
J Biol Chem. 1988 Jul 15;263(20):9557-60
pubmed: 3290208
Viruses. 2012 May;4(5):800-32
pubmed: 22754650
J Matern Fetal Neonatal Med. 2016;29(10):1657-64
pubmed: 26135794
Rev Med Virol. 2016 May;26(3):161-82
pubmed: 26990717
J Virol. 2005 Aug;79(16):10330-8
pubmed: 16051825
PLoS One. 2015 Feb 23;10(2):e0116278
pubmed: 25706563
Antiviral Res. 2001 Aug;51(2):141-9
pubmed: 11431038
Cancer Lett. 2014 Jan 1;342(1):1-8
pubmed: 24041869
J Immunol. 2009 Mar 1;182(5):3191-201
pubmed: 19234217
J Exp Med. 2014 Jun 30;211(7):1433-48
pubmed: 24958847
Clin Microbiol Rev. 2010 Oct;23(4):689-712
pubmed: 20930070
J Gen Virol. 2010 Jun;91(Pt 6):1535-46
pubmed: 20479471
Curr Opin Struct Biol. 2007 Oct;17(5):513-20
pubmed: 17950594
J Virol. 2009 Jun;83(12):6192-8
pubmed: 19357166
J Virol. 2004 Sep;78(18):10023-33
pubmed: 15331735
J Virol. 2004 Oct;78(20):10960-6
pubmed: 15452216
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3937-42
pubmed: 9520471
PLoS Pathog. 2016 Jun 02;12(6):e1005677
pubmed: 27253379
Antimicrob Agents Chemother. 2008 Mar;52(3):1111-20
pubmed: 18180342
J Virol. 2005 Nov;79(21):13326-37
pubmed: 16227255
Rev Med Virol. 2015 May;25(3):175-86
pubmed: 25760439
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18153-8
pubmed: 16319222
J Virol. 2013 May;87(9):4835-45
pubmed: 23408620
J Virol. 2014 Sep;88(18):10990-4
pubmed: 25008927
Tohoku J Exp Med. 2012;228(2):157-61
pubmed: 23038209
J Immunol. 2012 May 1;188(9):4631-43
pubmed: 22467659
J Virol. 2003 Apr;77(7):4326-44
pubmed: 12634390
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14118-23
pubmed: 18768787
Nat Rev Microbiol. 2009 Jun;7(6):424-38
pubmed: 19444247
AIDS Res Hum Retroviruses. 2014 Jul;30(7):654-64
pubmed: 24786365
Virol Sin. 2014 Dec;29(6):343-52
pubmed: 25501994
J Virol. 2011 Nov;85(22):11638-45
pubmed: 21880752
J Immunol. 2003 Dec 15;171(12):6733-41
pubmed: 14662877
BMC Cancer. 2006 Dec 08;6:283
pubmed: 17156439
Virology. 1992 Nov;191(1):387-95
pubmed: 1329327
N Engl J Med. 2017 Dec 21;377(25):2433-2444
pubmed: 29211658
Acta Biochim Pol. 2011;58(2):231-6
pubmed: 21681287
Tohoku J Exp Med. 2009 Aug;218(4):285-92
pubmed: 19638732
Antimicrob Agents Chemother. 2012 Jan;56(1):154-62
pubmed: 22064534
Blood. 2009 Feb 26;113(9):1957-66
pubmed: 19005181
PLoS Pathog. 2010 May 06;6(5):e1000882
pubmed: 20463811
PLoS Pathog. 2014 May 01;10(5):e1004058
pubmed: 24787765